Evidence map›Paper›PMID 36526722›Full record

ArticleNature medicine2022

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.

Chelsea A Taylor, Robert A Watson, Orion Tong, Weiyu Ye, Isar Nassiri, James J Gilchrist, Alba Verge de Los Aires, Piyush Kumar Sharma, Surya Koturan, Rosalin A Cooper and 15 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nature medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
42citing papers in PubMed, 1 pooled it
8.3field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

42 citing papers in PubMed, 1 synthesis or guideline pooled it, 68 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. B cells in cancer: functions, mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2026
    Review
  4. Article
  5. Article
  6. Association ofJournal of clinical medicine · 2026
    Article
  7. Review
  8. Review
  9. Genetic haplotypes inJournal for immunotherapy of cancer · 2025
    Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. IL-7-mediated expansion of autologous lymphocytes increases CD8bioRxiv : the preprint server for biology · 2025
    Article
  15. Article
  16. Review
  17. Drug-Induced Liver Injury Associated With Emerging Cancer Therapies.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

25 authors at 7 institutions in 3 countries.

Chelsea A Taylor *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-1635-4167
Robert A Watson *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Orion Tong *MRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-0659-5944
Weiyu YeMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-8983-0355
Isar NassiriMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
James J GilchristMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-2045-6788
Alba Verge de Los AiresMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Piyush Kumar SharmaMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0002-6247-3503
Surya KoturanMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Rosalin A CooperMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Victoria K WoodcockMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0001-7656-728X
Elsita JungkurthMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK.
Brian ShineDepartment of Clinical Biochemistry, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Oxford, UK.
Nicholas CoupeOxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
Miranda J PayneOxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.
David N ChurchOxford Cancer and Haematology Centre, Oxford University Hospitals NHS Foundation Trust, Churchill Hospital, Oxford, UK.ORCID http://orcid.org/0000-0002-4617-962X
Vivek NaranbhaiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Stefan GrohaDepartment of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.
Paul EmeryLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.ORCID http://orcid.org/0000-0002-7429-8482
Kulveer MankiaLeeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, UK.
Matthew L FreedmanDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.ORCID http://orcid.org/0000-0002-9201-3217
Mark R MiddletonDepartment of Oncology, University of Oxford, Oxford, UK.ORCID http://orcid.org/0000-0003-0167-1685
Alexander GusevDepartment of Medical Oncology, Division of Population Sciences, Dana-Farber Cancer Institute, Boston, MA, USA.ORCID http://orcid.org/0000-0002-7980-4620
Benjamin P FairfaxMRC Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, UK. benjamin.fairfax@oncology.ox.ac.uk.ORCID http://orcid.org/0000-0001-7413-5002
University of Oxford · GBChurchill Hospital · GBBroad Institute · USCentre for Human Genetics · GBUniversity of Leeds · GBHarvard University · USJohn Radcliffe Hospital · GB

Funding

Cancer Research UK 27963Cancer Research UK C26642/A27963Cancer Research UK RCCTI\100019Cancer Research UK S_3578Department of HealthWellcome Trust 201488/Z/16/ZWellcome Trust BST00070
6 · The paper itself

Abstract

Treatment with immune checkpoint blockade (ICB) frequently triggers immune-related adverse events (irAEs), causing considerable morbidity. In 214 patients receiving ICB for melanoma, we observed increased severe irAE risk in minor allele carriers of rs16906115, intronic to IL7. We found that rs16906115 forms a B cell-specific expression quantitative trait locus (eQTL) to IL7 in patients. Patients carrying the risk allele demonstrate increased pre-treatment B cell IL7 expression, which independently associates with irAE risk, divergent immunoglobulin expression and more B cell receptor mutations. Consistent with the role of IL-7 in T cell development, risk allele carriers have distinct ICB-induced CD8

Indexed as

Interleukin-7MelanomaCD8-Positive T-LymphocytesGenetic VariationHumansImmune Checkpoint InhibitorsImmune Checkpoint InhibitorsInterleukin-7

Identifiers

PMID36526722
PMCPMC9800275
OpenAlexW4311824944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.